CD8A and colon adenocarcinoma: In order to address mechanisms by which the anti‐RANKL/PD‐1 BsAb controls tumor growth, we examined whether the efficacy was dependent on IFNγ or CD8+ T cells in the more immunogenic MC38‐OVAdim colon adenocarcinoma model.